Missouri Reports First Cases of Severe Mpox Strain Following International Travel
Jefferson City, Saturday, 21 March 2026.
Missouri confirmed its first two cases of a severe mpox variant linked to international travel, marking the 14th national case and prompting employers to review workplace health protocols.
Assessing the Clade I Variant and Workplace Implications
On March 19 and March 20, 2026, the Missouri Department of Health and Senior Services (DHSS) identified two adult residents infected with the Clade I mpox virus [3][6]. These diagnoses represent the first known instances of this specific strain in Missouri and the 13th and 14th cases recorded nationally [1][3][5]. By the numbers, these two recent Missouri cases account for approximately 14.286 percent of the total known national Clade I infections to date [1][3]. Public health investigations revealed that both individuals had recently returned from international travel in regions where the virus is prevalent [1][2]. The cases are completely unrelated to each other, and officials do not believe they are connected to any locally acquired infections [1][4][8]
Transmission Dynamics and Corporate Health Strategy
The progression of the disease demands careful monitoring by both individuals and occupational health teams, as symptoms typically manifest within three weeks of exposure [4]. Infected individuals may initially experience a combination of fever, chills, headache, exhaustion, muscle aches, sore throat, or swollen lymph nodes [1][6]. This is often followed by an infectious rash that can resemble painful or itchy pimples and blisters [1][2]. Over time, these skin lesions develop scabs or crusts before eventually resolving [7]. A crucial factor for human resources and medical leave policies is the duration of isolation required; a person remains contagious from the onset of symptoms until the rash has fully healed and a fresh layer of skin has formed, a process that can take several weeks [4][7].
Vaccination Protocols and Preventative Measures
To mitigate the spread and protect vulnerable populations, health officials are strongly recommending the JYNNEOS vaccine for individuals at elevated risk [2][4]. The vaccination protocol requires a two-dose series, with the second shot administered at least 28 days after the initial dose to achieve maximum protection [4][6]. Routine vaccination is not currently advised for the general public without specific risk factors [4]. Furthermore, individuals who have already recovered from an mpox infection do not require vaccination [6][7].